Health ❯ Obesity ❯ Treatment Options

Oral Medications

GLP-1 Drugs Foundayo FDA Approval Patient Adherence Drug Efficacy GLP-1 Agonists GLP-1 Therapies Wegovy Pill

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3